Alexander Vos
Directeur/Membre du Conseil chez ALPHA TEKNOVA, INC.
Fortune : 65 996 $ au 30/06/2024
Profil
Alexander Vos is currently an Independent Director at Alpha Teknova, Inc., a Director at InnoCore Technologies BV, a Director at Roslin Cell Therapies Ltd., a Venture Partner at Biogeneration Management BV, and a Member-Supervisory Board at CiMaas BV.
Previously, he served as the Chief Executive Officer of PharmaCell BV from 2009 to 2017, the Chief Executive Officer of MediService AG in 2004, the Chief Executive Officer of VarmX BV from 2018 to 2021, and the Chief Executive Officer of VectorY BV from 2021 to 2022.
He also held the position of Chairman-Supervisory Board at Symeres BV from 2018 to 2021.
Additionally, Mr. Vos has experience as a Director of Business Development at Genzyme Therapeutics Ltd., a Director-Supervisory Board at Medisse BV, a Director at the Alliance for Regenerative Medicine from 2015 to 2018, and the Chief Operating Officer at PAION AG from 2004 to 2013.
He started his career as a Strategy Consultant at McKinsey & Co., Inc. Mr. Vos obtained his undergraduate and graduate degrees from the University of Amsterdam and holds an MBA from Stanford Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALPHA TEKNOVA, INC.
0,12% | 26/06/2024 | 48 172 ( 0,12% ) | 65 996 $ | 30/06/2024 |
Postes actifs de Alexander Vos
| Sociétés | Poste | Début |
|---|---|---|
| ALPHA TEKNOVA, INC. | Directeur/Membre du Conseil | 01/06/2021 |
InnoCore Technologies BV
 InnoCore Technologies BV Pharmaceuticals: MajorHealth Technology InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands. | Directeur/Membre du Conseil | - |
CiMaas BV
 CiMaas BV BiotechnologyHealth Technology CiMaas BV develops cellular immunotherapy for cancer. Its products include cancer vaccine using the patient's own immune cells and the production of donor natural killer cells. The company was founded by Gerard M.J. Bos and Dilfred T.V. Germeraad and is headquartered in Maastricht, the Netherlands. | Directeur/Membre du Conseil | 01/09/2018 |
Biogeneration Management BV
 Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Private Equity Investor | 01/07/2019 |
Roslin Cell Therapies Ltd.
 Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alexander Vos
| Sociétés | Poste | Fin |
|---|---|---|
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Directeur Général | 08/11/2022 |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Directeur Général | 15/06/2021 |
Symeres BV
 Symeres BV Pharmaceuticals: OtherHealth Technology Symeres provides molecule contract research, discovery, development and manufacturing services. The firm offers discovery chemistry, medicinal chemistry, early process research and GMP production services. The company is headquartered in Groningen, the Netherlands. | Président | 01/05/2021 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Directeur/Membre du Conseil | 01/05/2018 |
| ░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Alexander Vos
| University of Amsterdam | Graduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PAION AG | Health Technology |
| ALPHA TEKNOVA, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
PharmaCell BV
 PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | Health Technology |
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Finance |
MediService AG
 MediService AG Drugstore ChainsRetail Trade MediService AG is a mail service pharmacy. The company is headquartered in Zuchwil, Switzerland. | Retail Trade |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
InnoCore Technologies BV
InnoCore Technologies BV Pharmaceuticals: MajorHealth Technology InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands. | Health Technology |
Medisse BV
 Medisse BV Medical SpecialtiesHealth Technology Medisse BV develops resorbable medical implants based on a flexible material. Its products include FlexiSurge Adhesion Barrier, Hernia Mesh and Scleral Buckle. The company was founded by Sandra de Vos, Dirk W. Grijpma and Jan Feijen in 2006 and is headquartered in Ede, the Netherlands. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
CiMaas BV
CiMaas BV BiotechnologyHealth Technology CiMaas BV develops cellular immunotherapy for cancer. Its products include cancer vaccine using the patient's own immune cells and the production of donor natural killer cells. The company was founded by Gerard M.J. Bos and Dilfred T.V. Germeraad and is headquartered in Maastricht, the Netherlands. | Health Technology |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Health Technology |
Symeres BV
Symeres BV Pharmaceuticals: OtherHealth Technology Symeres provides molecule contract research, discovery, development and manufacturing services. The firm offers discovery chemistry, medicinal chemistry, early process research and GMP production services. The company is headquartered in Groningen, the Netherlands. | Health Technology |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Commercial Services |
